American Association for Cancer Research
Browse

Table S1-S5 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy

Download (502.53 kB)
dataset
posted on 2025-05-15, 12:44 authored by Xiao Yang, Yue Deng, Ying Ye, Jingshu Meng, Mengyao Su, Wenwen Wei, You Qin, Haibo Zhang, Yu Tian, Suke Deng, Zhiyun Liao, Zhiyuan Zhou, Jie Li, Yan Hu, Bin Zhang, Yajie Sun, Lu Wen, Zhanjie Zhang, Fang Huang, Chao Wan, Kunyu Yang
<p>Table S1 presents the sequences of primers used for RT-qPCR analysis. Table S2 lists the sequences of primers used for ChIP-PCR. Table S3 contains the differentially expressed metabolites identified in tumor tissues of Lewis tumor-bearing mice treated with IgG2 (Ctrl) or anti-PD-1 monoclonal antibody. Table S4 summarizes the differentially expressed genes in untreated and IFN-γ-treated bone marrow-derived macrophages (BMDMs). Table S5 provides the differentially expressed genes in bone marrow-derived dendritic cells (BMDCs) under IFN-γ versus IFN-γ + 4-OI treatment conditions.</p>

Funding

the National Natural Science Foundation of China

National Natural Science Foundation of China (NSFC)

History

ARTICLE ABSTRACT

Adaptive resistance to immunotherapy remains a significant challenge in cancer treatment. The reshaping of the tumor immune microenvironment in response to therapeutic pressures is a crucial factor contributing to this resistance. In this study, by comprehensive metabolic profiling of tumor tissues, we identified elevated itaconate in response to anti–PD-1 therapy as an adaptive resistance mechanism that promoted immune escape and tumor progression. CD8+ T-cell–derived IFNγ induced a significant upregulation of cis-aconitate decarboxylase 1 (ACOD1) in macrophages via the JAK–STAT1 pathway, thereby rewiring the Krebs cycle toward itaconate production. In murine models, macrophage-specific deletion of Acod1 increased the antitumor efficacy of anti–PD-1 therapy and improved survival. Additionally, itaconate and its derivative, 4-octyl itaconate, suppressed the tumor antigen presentation and cross-priming ability of dendritic cells, resulting in the impairment of antigen-specific T-cell antitumor responses. In summary, these findings identify an IFNγ-dependent immunometabolic mechanism of anti–PD-1 resistance, providing a promising strategy for combination therapy.Significance: Elevated itaconate production by macrophages induced by IFNγ is a critical negative feedback immunoregulatory metabolic response to anti-PD-1 immunotherapy that inhibits the cross-priming function of dendritic cells and confers immunotherapy resistance.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC